Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial

AIM: To evaluate the lipid‐lowering efficacy and safety of evolocumab combined with background atorvastatin in patients with type 2 diabetes mellitus (T2DM) and hyperlipidaemia or mixed dyslipidaemia. MATERIALS AND METHODS: BERSON was a double‐blind, 12‐week, phase 3 study (NCT02662569) conducted in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorenzatti, Alberto J., Eliaschewitz, Freddy G., Chen, Yundai, Lu, Juming, Baass, Alexis, Monsalvo, Maria Laura, Wang, Nan, Hamer, Andrew W., Ge, Junbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594020/
https://www.ncbi.nlm.nih.gov/pubmed/30821053
http://dx.doi.org/10.1111/dom.13680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594020/
https://www.ncbi.nlm.nih.gov/pubmed/30821053
http://dx.doi.org/10.1111/dom.13680

Ejemplares similares